Guardant Health's Shield blood test for colorectal cancer screening is now covered by TRICARE, providing active duty service ...

The ROAR trial tested the hypothesis that returning familial hypercholesterolemia-associated genetic results leads to ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for ...

"The question is, are these changes done unilaterally by the executive going to stand the test of time as a powerful ...

A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret ...

Investigators designed and externally validated a prostate cancer death prediction model for risk stratification of men at the point of PSA screening.

Model was developed from the prostate cancer screening group of the PLCO and validated externally in a VA population ...

The past year has been traumatic for many of the volunteer tech warriors of what was once called the United States Digital ...

Despite claims to “drain the swamp” and cut wasteful government spending, and despite the efforts of Elon Musk and a new Department of Government Efficiency, federal ...

What’s more, he explained, several groups have examined existing databases (e.g. Optum, prior clinical trials in IPF, registries) and suggested that metformin therapy in people wiht diabetes with IPF ...

The legalized marijuana industry pushes to eliminate hemp as a competing market, and state governments are its chosen tools.

Partnership Leverages Callan JMB's Federal Contract Experience, Cold Chain Infrastructure, and Strategic National Stockpile Relationships to ...